Skip to main content
SpringerLink
Log in

Principles of Pharmacogenomics and Pharmacogenetics

  • Chapter
  • First Online:
Precision Medicine in Clinical Practice

  • 779 Accesses

Abstract

Pharmacogenomics (Pharmacogenetics) (PGx) is one of the most important components of personalized medicine which focuses on the association between genetic variations and drug response. Pharmacogenomics can help physicians decide drug selection, dose adjustment, and treatment period and prevent adverse drug reactions. Specific genetic variations have been related to clinically significant changes in drug disposition between individuals, including vulnerability to adverse drug responses and therapeutic response or efficacy. There is a substantial amount of scientific evidence supporting the utility of pharmacogenomics testing in patient management. Oncology pharmacogenomics is more complex than pharmacogenomics in other disease states because clinical concerns can be considered for tumor’s somatic genome and the patient’s germline genome. Pharmacogenomics is vital in identifying the genes related to the response in psycho-pharmacotherapeutic agents to improve treatment outcomes. Many diabetic patients fail to achieve optimal glycemic control. The degree to which oral antidiabetic drugs are efficient or cause adverse drug reactions (ADR) significantly varies within the T2DM population. The treatment outcome of these agents depends on genetic variation in a plethora of genes. The present chapter focuses on the major discoveries on pharmacogenomics journey and gives insights into the future of pharmacogenomics in medical disciplines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 89.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Meyer UA. Pharmacogenetics–five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;5(9):669.

    Article  CAS  PubMed  Google Scholar 

  2. Relling MV, McDonagh EM, Chang T, Caudle KE, McLeod HL, Haidar CE, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin Pharmacol Ther. 2014;96(2):169–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Garrod AE. Inborn errors of metabolism: H. London: Frowde and Hodder & Stoughton; 1909.

    Google Scholar 

  4. Gonzalez FJ, Skoda RC, Kimura S, Umeno M, Zanger UM, Nebert DW, et al. Characterization of the common genetic defect in humans deficient in debrisoquine metabolism. Nature. 1988;331(6155):442–6.

    Article  CAS  PubMed  Google Scholar 

  5. Food, Drug Administration HHS. International conference on harmonisation; guidance on E15 pharmacogenomics definitions and sample coding; availability. Notice. Federal register. 2008;73(68):19074–6.

    Google Scholar 

  6. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15(2):209–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Giri J, Moyer AM, Bielinski SJ, Caraballo PJ. Concepts driving pharmacogenomics implementation into everyday healthcare. Pharmgenomics Pers Med. 2019;12:305–18.

    PubMed  PubMed Central  Google Scholar 

  9. van den Anker J, Reed MD, Allegaert K, Kearns GL. Developmental changes in pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 2018;58(Suppl 10):S10–s25.

    Article  PubMed  Google Scholar 

  10. van den Anker JN, Schwab M, Kearns GL. Developmental pharmacokinetics. Handb Exp Pharmacol. 2011;205:51–75.

    Article  PubMed  Google Scholar 

  11. DiPiro J, Spruill W, Wade W, Blouin R, Pruemer J. Introduction to pharmacokinetics and pharmacodynamics. In: Concepts in clinical pharmacokinetics, vol. 5. Bethesda, MD: American Society of Health-System Pharmacists; 2010.

    Google Scholar 

  12. Cacabelos R, Cacabelos N, Carril JC. The role of pharmacogenomics in adverse drug reactions. Expert Rev Clin Pharmacol. 2019;12(5):407–42.

    Article  CAS  PubMed  Google Scholar 

  13. Currie GM. Pharmacology, part 1: introduction to pharmacology and pharmacodynamics. J Nucl Med Technol. 2018;46(2):81–6.

    Article  PubMed  Google Scholar 

  14. Lista AD, Sirimaturos M. Pharmacokinetic and Pharmacodynamic principles for toxicology. Crit Care Clin. 2021;37(3):475–86.

    Article  PubMed  Google Scholar 

  15. Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, et al. Pharmacokinetic/pharmacodynamic modeling in drug research and development. J Clin Pharmacol. 2000;40(12 Pt 2):1399–418.

    Article  CAS  PubMed  Google Scholar 

  16. Abdel-Rahman SM, Kauffman RE. The integration of pharmacokinetics and pharmacodynamics: understanding dose-response. Annu Rev Pharmacol Toxicol. 2004;44:111–36.

    Article  CAS  PubMed  Google Scholar 

  17. Cicali EJ, Elchynski AL, Cook KJ, Houder JT, Thomas CD, Smith DM, et al. How to integrate CYP2D6 Phenoconversion into clinical Pharmacogenetics: a tutorial. Clin Pharmacol Ther. 2021;110(3):677–87.

    Article  PubMed  Google Scholar 

  18. Shah RR, Smith RL. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol. 2015;79(2):222–40.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine. Drug Metab Dispos. 2015;43(3):400–10.

    Article  PubMed  Google Scholar 

  20. Klomp SD, Manson ML, Guchelaar HJ, Swen JJ. Phenoconversion of cytochrome P450 metabolism: a systematic review. J Clin Med. 2020;9(9):2890.

    Article  CAS  PubMed Central  Google Scholar 

  21. University of Florida Health (UFHealth). Precision Medicine Program; CYP2D6 Phenoconversion Calculator. https://precisionmedicineufhealthorg/phenoconversion-calculator/.

    Google Scholar 

  22. Mostafa S, Polasek TM, Sheffield LJ, Huppert D, Kirkpatrick CM. Quantifying the impact of Phenoconversion on medications with actionable Pharmacogenomic guideline recommendations in an acute aged persons mental health setting. Front Psych. 2021;12:724170.

    Article  Google Scholar 

  23. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, et al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet Med. 2017;19(2):215–23.

    Article  PubMed  Google Scholar 

  24. Group ISMW. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature. 2001;409(6822):928–33.

    Article  Google Scholar 

  25. Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92(4):467–75.

    CAS  PubMed  Google Scholar 

  26. Calvo E, Walko C, Dees EC, Valenzuela B. Pharmacogenomics, pharmacokinetics, and pharmacodynamics in the era of targeted therapies. Am Soc Clin Oncol Educ Book. 2016;36:e175–84.

    Article  Google Scholar 

  27. Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF, et al. Pharmacogenomics. Lancet (London, England). 2019;394(10197):521–32.

    Article  CAS  Google Scholar 

  28. Lynch T, Price AL. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76(3):391–6.

    PubMed  Google Scholar 

  29. Budd WT, Meyers G, Dilts JR, O'Hanlon K, Woody JR, Bostwick DG, et al. Next generation sequencing reveals disparate population frequencies among cytochrome P450 genes: clinical pharmacogenomics of the CYP2 family. Int J Comput Biol Drug Des. 2016;9(1–2):54–86.

    Article  Google Scholar 

  30. US Food and Drug Administration (FDA). Paving the way for personalized medicine: FDA’s role in a new era of medical product development. https://www.fdanewscom/ext/resources/files/10/10-28-13-Personalized-Medicinepdf (Accessed 26 Nov 2019).

  31. Relling M, Klein T. CPIC: Clinical Pharmacogenetics Implementation Consortium of the pharmacogenomics research network. Clin Pharmacol Ther. 2011;89(3):464–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Picard N, Boyer J-C, Etienne-Grimaldi M-C, Barin-Le Guellec C, Thomas F, Loriot M-A, et al. Pharmacogenetics-based personalized therapy: levels of evidence and recommendations from the French Network of Pharmacogenetics (RNPGx). Therapies. 2017;72(2):185–92.

    Article  Google Scholar 

  33. Guo C, Xie X, Li J, Huang L, Chen S, Li X, et al. Pharmacogenomics guidelines: current status and future development. Clin Exp Pharmacol Physiol. 2019;46(8):689–93.

    Article  CAS  PubMed  Google Scholar 

  34. Cheng CM, So TW, Bubp JL. Characterization of Pharmacogenetic information in Food and Drug Administration drug labeling and the table of Pharmacogenetic associations. Ann Pharmacother. 2020;55(10):1185–94.

    Article  PubMed  Google Scholar 

  35. Mehta D, Uber R, Ingle T, Li C, Liu Z, Thakkar S, et al. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine. Drug Discov Today. 2020;25(5):813–20.

    Article  PubMed  Google Scholar 

  36. US Food and Drug Administration (FDA). Table of Pharmacogenomic Biomarkers in Drug Labeling. https://www.fdagov/drugs/science-and-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling. (Accessed 8 Mar 2020).

  37. US Food and Drug Administration (FDA). Table of Pharmacogenetic Associations. https://www.fdagov/medical-devices/precision-medicine/table-pharmacogenetic-associations. (Accessed 3 Mar 2020).

  38. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside. Focus. 2006;3(3):739–441.

    Google Scholar 

  39. Wysocki K, Seibert D. Pharmacogenomics in clinical care. J Am Assoc Nurse Pract. 2019;31(8):443–6.

    Article  PubMed  Google Scholar 

  40. Centers for Disease Control and Prevention. Medication Safety Program; Adverse Drug Events in Adults. https://www.cdcgov/medicationsafety/adult_adversedrugeventshtml.

  41. Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin Pharmacol Ther. 2010;87(3):356–61.

    Article  CAS  PubMed  Google Scholar 

  42. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000–2009. Clin Pharmacol Ther. 2011;89(2):183–8.

    Article  CAS  PubMed  Google Scholar 

  43. Morgan P, Brown DG, Lennard S, Anderton MJ, Barrett JC, Eriksson U, et al. Impact of a five-dimensional framework on R & D productivity at AstraZeneca. Nat Rev Drug Discov. 2018;17(3):167–81.

    Article  CAS  PubMed  Google Scholar 

  44. Check HE. Technology: the $1,000 genome. Nat News. 2014;507(7492):294.

    Article  Google Scholar 

  45. Maliepaard M, Nofziger C, Papaluca M, Zineh I, Uyama Y, Prasad K, et al. Pharmacogenetics in the evaluation of new drugs: a multiregional regulatory perspective. Nat Rev Drug Discov. 2013;12(2):103–15.

    Article  CAS  PubMed  Google Scholar 

  46. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

    Article  PubMed  Google Scholar 

  47. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  48. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291(5507):1304–51.

    Article  CAS  PubMed  Google Scholar 

  49. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011;17(3):297–303.

    Article  CAS  PubMed  Google Scholar 

  50. Hasanzad M, Sarhangi N, Aghaei Meybodi HR, Nikfar S, Khatami F, Larijani B. Precision medicine in non communicable diseases. Int J Mol Cell Med. 2019;8(Suppl1):1–18.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. Olopade O, Pichert G. Cancer genetics in oncology practice. Ann Oncol. 2001;12(7):895–908.

    Article  CAS  PubMed  Google Scholar 

  52. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11(10):685–96.

    Article  CAS  PubMed  Google Scholar 

  53. National Comprehensive Cancer Network (NCCN). https://www.nccnorg/.

  54. Wheeler HE, Maitland ML, Dolan ME, Cox NJ, Ratain MJ. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013;14(1):23.

    Article  CAS  PubMed  Google Scholar 

  55. Del Re M, Citi V, Crucitta S, Rofi E, Belcari F, van Schaik RH, et al. Pharmacogenetics of CYP2D6 and tamoxifen therapy: light at the end of the tunnel? Pharmacol Res. 2016;107:398–406.

    Article  PubMed  Google Scholar 

  56. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, et al. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics. 2001;11(7):573–85.

    Article  CAS  PubMed  Google Scholar 

  57. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92(4):414–7.

    Article  CAS  PubMed  Google Scholar 

  58. Whirl-Carrillo M, Huddart R, Gong L, Sangkuhl K, Thorn CF, Whaley R, et al. An evidence-based framework for evaluating pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2021;110(3):563–72.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Goetz MP, Sangkuhl K, Guchelaar HJ, Schwab M, Province M, Whirl-Carrillo M, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and tamoxifen therapy. Clin Pharmacol Ther. 2018;103(5):770–7.

    Article  PubMed  Google Scholar 

  60. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103(2):210–6.

    Article  CAS  PubMed  Google Scholar 

  61. Vahratian A, Blumberg SJ, Terlizzi EP, Schiller JS. Symptoms of anxiety or depressive disorder and use of mental health care among adults during the COVID-19 pandemic—United States, August 2020–February 2021. MMWR Morb Mortal Wkly Rep. 2021;70(13):490–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Corponi F, Fabbri C, Serretti A. Pharmacogenetics in psychiatry. Adv Pharmacol. 2018;83:297–331.

    Article  CAS  PubMed  Google Scholar 

  63. Amare AT, Schubert KO, Baune BT. Pharmacogenomics in the treatment of mood disorders: strategies and opportunities for personalized psychiatry. EPMA J. 2017;8(3):211–27.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatr. 2010;55(3):126–35.

    Article  Google Scholar 

  65. Panza F, Lozupone M, Stella E, Lofano L, Gravina C, Urbano M, et al. Psychiatry meets pharmacogenetics for the treatment of revolving door patients with psychiatric disorders. Expert Rev Neurother. 2016;16(12):1357–69.

    Article  CAS  PubMed  Google Scholar 

  66. Müller DJ, Rizhanovsky Z. From the origins of pharmacogenetics to first applications in psychiatry. Pharmacopsychiatry. 2020;53(4):155–61.

    Article  PubMed  Google Scholar 

  67. Murphy LE, Fonseka TM, Bousman CA, Muller DJ. Gene-drug pairings for antidepressants and antipsychotics: level of evidence and clinical application. Mol Psychiatry. 2022;27:593–605.

    Article  CAS  PubMed  Google Scholar 

  68. Murphy DL, Moya PR. Human serotonin transporter gene (SLC6A4) variants: their contributions to understanding pharmacogenomic and other functional G×G and G×E differences in health and disease. Curr Opin Pharmacol. 2011;11(1):3–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Peiró AM, Planelles B, Juhasz G, Bagdy G, Libert F, Eschalier A, et al. Pharmacogenomics in pain treatment. Drug Metab Pers Ther. 2016;31(3):131–42.

    PubMed  Google Scholar 

  70. Saba R, Kaye AD, Urman RD. Pharmacogenomics in pain management. Anesthesiol Clin. 2017;35(2):295–304.

    Article  PubMed  Google Scholar 

  71. Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The clinical pharmacogenetics implementation consortium: 10 years later. Clin Pharmacol Ther. 2020;107(1):171–5.

    Article  PubMed  Google Scholar 

  72. Hoffman JM, Dunnenberger HM, Kevin Hicks J, Caudle KE, Whirl Carrillo M, Freimuth RR, et al. Developing knowledge resources to support precision medicine: principles from the Clinical Pharmacogenetics Implementation Consortium (CPIC). J Am Med Inform Assoc. 2016;23(4):796–801.

    Article  PubMed  PubMed Central  Google Scholar 

  73. Caudle KE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Relling MV, Klein TE. Evidence and resources to implement pharmacogenetic knowledge for precision medicine. Am J Health Syst Pharm. 2016;73(23):1977–85.

    Article  CAS  PubMed  Google Scholar 

  74. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021;183:109119.

    Article  PubMed  Google Scholar 

  75. Committee ADAPP, Committee: ADAPP. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S17–38.

    Article  Google Scholar 

  76. Committee ADAPP, Committee: ADAPP. 6. Glycemic targets: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S83–96.

    Article  Google Scholar 

  77. Committee ADAPP, Committee: ADAPP. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S125–S43.

    Article  Google Scholar 

  78. Alomar MJ. Factors affecting the development of adverse drug reactions. Saudi Pharm J. 2014;22(2):83–94.

    Article  PubMed  Google Scholar 

  79. Davies E, O'mahony M. Adverse drug reactions in special populations–the elderly. Br J Clin Pharmacol. 2015;80(4):796–807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM. Integrating rare genetic variants into pharmacogenetic drug response predictions. Hum Genomics. 2018;12(1):1–12.

    Article  Google Scholar 

  81. Mannino GC, Andreozzi F. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. Diabetes Metab Res Rev. 2019;35(3):e3109.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Heo CU, Choi CI. Current progress in pharmacogenetics of second-line antidiabetic medications: towards precision medicine for type 2 diabetes. J Clin Med. 2019;8(3):393.

    Article  CAS  PubMed Central  Google Scholar 

  83. Pearson ER. Pharmacogenetics and target identification in diabetes. Curr Opin Genet Dev. 2018;50:68–73.

    Article  CAS  PubMed  Google Scholar 

  84. Cai L, Wheeler E, Kerrison ND, Ja L, Deloukas P, Franks PW, et al. Genome-wide association analysis of type 2 diabetes in the EPIC-InterAct study. Sci Data. 2020;7(1):393.

    Article  PubMed  PubMed Central  Google Scholar 

  85. Franks PW, McCarthy MI. Exposing the exposures responsible for type 2 diabetes and obesity. Science. 2016;354(6308):69–73.

    Article  CAS  PubMed  Google Scholar 

  86. Huang C, Florez JC. Pharmacogenetics in type 2 diabetes: potential implications for clinical practice. Genome Med. 2011;3(11):76.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Mannino GC, Andreozzi F, Sesti G. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine. Diabetes Metab Res Rev. 2019;35(3):e3109.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Nasykhova YA, Tonyan ZN, Mikhailova AA, Danilova MM, Glotov AS. Pharmacogenetics of type 2 diabetes-progress and prospects. Int J Mol Sci. 2020;21(18):6842.

    Article  CAS  PubMed Central  Google Scholar 

  89. Ordelheide AM, Hrabe de Angelis M, Haring HU, Staiger H. Pharmacogenetics of oral antidiabetic therapy. Pharmacogenomics. 2018;19(6):577–87.

    Article  CAS  PubMed  Google Scholar 

  90. Florez JC. The pharmacogenetics of metformin. Diabetologia. 2017;60(9):1648–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Xhakaza L, Abrahams-October Z, Pearce B, Masilela CM, Adeniyi OV, Johnson R, et al. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients. Drug Metab Pers Ther. 2020;35(2) https://doi.org/10.1515/dmdi-2020-0111.

  92. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, et al. Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management. Front Endocrinol. 2017;8:6.

    Article  Google Scholar 

  93. Loganadan NK, Huri HZ, Vethakkan SR, Hussein Z. Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. Pharmacogenomics J. 2016;16(3):209–19.

    Article  CAS  PubMed  Google Scholar 

  94. Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E. Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev. 2011;27(4):362–72.

    Article  CAS  PubMed  Google Scholar 

  95. Rathmann W, Bongaerts B. Pharmacogenetics of novel glucose-lowering drugs. Diabetologia. 2021;64(6):1201–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Personalized Medicine Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran

    Mandana Hasanzad & Negar Sarhangi

  2. Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

    Mandana Hasanzad & Leila Hashemian

  3. Creighton University School of Pharmacy and Health Professions, Omaha, NE, USA

    Behnaz Sarrami

Authors
  1. Mandana Hasanzad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Negar Sarhangi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Leila Hashemian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Behnaz Sarrami
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran

    Mandana Hasanzad

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Hasanzad, M., Sarhangi, N., Hashemian, L., Sarrami, B. (2022). Principles of Pharmacogenomics and Pharmacogenetics. In: Hasanzad, M. (eds) Precision Medicine in Clinical Practice. Springer, Singapore. https://doi.org/10.1007/978-981-19-5082-7_2

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-5082-7_2

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-5081-0

  • Online ISBN: 978-981-19-5082-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation